Novel delivery methods for treatment of viral hepatitis: an update.
Viral hepatitis represents the most common cause of chronic liver disease worldwide. Currently approved therapies for chronic hepatitis B include IFN, an immune modulator, and nucleoside analogues lamivudine and adefovir. For chronic hepatitis C, a combination of pegylated IFN-alpha and ribavirin represents the standard treatment. However, currently available treatments for both these viruses are effective only in a limited number of patients, are costly, prolonged, associated with significant side effects and require a substantial commitment from the patients and healthcare providers. A number of novel antiviral treatments, together with strategies to enhance the response to current therapies, are being explored at present. For all new therapies, as well as for improving existing treatments, selective delivery of medications into liver cells would be desirable to enhance antiviral activity and avoid systemic side effects. New achievements in the field of drug and gene delivery against chronic hepatitis to the liver are reviewed here.
Virovic
Lucija
L
University of Connecticut Health Center, Department of Medicine/GI Division, Farmington, 06030-1845, USA.
Wu
Catherine H
CH
Konishi
Masayoshi
M
Wu
George Y
GY
D000998:Antiviral Agents / Q000008:administration & dosage*; D037263:Asialoglycoprotein Receptor / Q000378:metabolism; D016503:Drug Delivery Systems; D015316:Genetic Therapy / Q000379:methods*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D008081:Liposomes; D049329:Nanostructures; D014677:Pharmaceutical Vehicles; D011107:Polylysine / Q000008:administration & dosage; D012709:Serum Albumin / Q000008:administration & dosage
D000998:Antiviral Agents; D037263:Asialoglycoprotein Receptor; D008081:Liposomes; D014677:Pharmaceutical Vehicles; D012709:Serum Albumin; D011107:Polylysine